The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
The RAAS in the pathogenesis and treatment of diabetic nephropathy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,527
(2000) · PubMed · Cited by 2,095
Ondetti, M. A., Rubin, B., & Cushman, D. W. (1977) · Science · doi:10.1126/science.191908 · Cited by 1,856
Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
The CAFE Investigators, CAFE Steering Committee and Writing Committee, Williams, B., Lacy, P. S., Thom, S. M., Cruickshank, K., Stanton, A., Collier, D., Hughes, A. D., Thurston, H., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.595496 · Cited by 1,645
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Longitudinal Studies on the Rate of Decline in Renal Function with Age
Lindeman, R. D., Tobin, J., & Shock, N. W. (1985) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1985.tb07117.x · Cited by 1,578
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Nguyen, G., Delarue, F., Burcklé, C., Bouzhir-Sima, L., Giller, T., & Sraer, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14276 · Cited by 1,276
Zatz, R., Dunn, B. R., Meyer, T. W., Anderson, S., Rennke, H. G., & Brenner, B. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112521 · Cited by 1,209
Estacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N., & Schrier, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803053381003 · Cited by 1,166
Nguyen, G., Delarue, F., Burcklé, C., Bouzhir, L., Giller, T., & Sraer, J.-D. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214276 · Cited by 1,137
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., & Hollenberg, N. K. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708379 · Cited by 1,098
Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W., & Cooper, M. E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1440 · Cited by 1,037
Preventing Microalbuminuria in Type 2 Diabetes
Ruggenenti, P., Fassi, A., Ilieva, A. P., Bruno, S., Iliev, I. P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042167 · Cited by 1,020
Self-citationAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
Barnett, A. H., Bain, S. C., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J., & Mustonen, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042274 · Cited by 910
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Circulation · doi:10.1161/01.cir.0000139860.33974.28 · Cited by 750
Self-citationCasas, J. P., Chua, W., Loukogeorgakis, S., Vallance, P., Smeeth, L., Hingorani, A. D., & MacAllister, R. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67814-2 · Cited by 745
Effect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737
The link between abdominal obesity, metabolic syndrome and cardiovascular disease
Ritchie, S. A., & Connell, J. M. C. (2007) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2006.07.005 · Cited by 726
Johnson, M. H. (1996) · Europe PMC (PubMed Central) · Cited by 651
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
Remuzzi, G. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27699 · Cited by 618
Self-citationPaget's Disease of the Mandible
Patel, M. B., & Bhalla, A. (2008) · New England Journal of Medicine · doi:10.1056/nejmicm066227 · Cited by 610
The renin-angiotensin-aldosterone system: Past, present and future
Vecsei, P., Hackenthal, E., & Ganten, D. (1978) · Klinische Wochenschrift · doi:10.1007/bf01477448 · Cited by 604
Carey, R. M., & Siragy, H. M. (2003) · Endocrine Reviews · doi:10.1210/er.2003-0001 · Cited by 603
Chaturvedi, N. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10244-0 · Cited by 518
Williams, K. J., & Tabas, I. (2006) · Circulation · doi:10.1161/circulationaha.105.606962 · Cited by 486
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459
Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function
KASCHINA, E., & UNGER, T. (2003) · Blood Pressure · doi:10.1080/08037050310001057 · Cited by 458
Ichihara, A., Hayashi, M., Kaneshiro, Y., Suzuki, F., Nakagawa, T., Tada, Y., Koura, Y., Nishiyama, A., Okada, H., Uddin, M. N., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421398 · Cited by 456
Abuissa, H., Jones, P. G., Marso, S. P., & O’Keefe, J. H. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.051 · Cited by 452
Chaturvedi, N., Porta, M., Klein, R., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., & Sjølie, A. K. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61412-9 · Cited by 451
Gall, M.-A., Hougaard, P., Borch-Johnsen, K., & Parving, H.-H. (1997) · BMJ · doi:10.1136/bmj.314.7083.783 · Cited by 445
Renal protective effect of enalapril in diabetic nephropathy.
Bjorck, S., Mulec, H., Johnsen, S. A., Norden, G., & Aurell, M. (1992) · BMJ · doi:10.1136/bmj.304.6823.339 · Cited by 432
The incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0575 · Cited by 420
Effect of Captopril on Heavy Proteinuria in Azotemic Diabetics
Taguma, Y., Kitamoto, Y., Futaki, G., Ueda, H., Monma, H., Ishizaki, M., Takahashi, H., Sekino, H., & Sasaki, Y. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512263132601 · Cited by 412
The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease
Brewster, U. C., & Perazella, M. A. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.034 · Cited by 390
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Viberti, G. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510280037029 · Cited by 381
Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan
Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D., & Navis, G. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007060693 · Cited by 372
The ACE Inhibitors in Diabetic Nephropathy Trialist Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-5-200103060-00009 · Cited by 343
Bianchi, S., Bigazzi, R., & Campese, V. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001854 · Cited by 338
Brenner, B. M. (1996) · Cited by 330
Parving, H. H., Hommel, E., & Smidt, U. M. (1988) · BMJ · doi:10.1136/bmj.297.6656.1086 · Cited by 328
Chaturvedi, N. (2001) · UCL Discovery (University College London) · Cited by 299
A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone
Struthers, A., Krum, H., & Williams, G. H. (2008) · Clinical Cardiology · doi:10.1002/clc.20324 · Cited by 267
Chrysostomou, A., & Becker, G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200109203451215 · Cited by 267
Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R., & Strippoli, G. F. M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04750908 · Cited by 258
Bilous, R., Chaturvedi, N., Sjølie, A. K., Fuller, J., Klein, R., Orchard, T., Porta, M., & Parving, H.-H. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-1-200907070-00120 · Cited by 252
Hou, F. F., Xie, D., Zhang, X., Chen, P. Y., Zhang, W. R., Liang, M., Guo, Z. J., & Jiang, J. P. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121372 · Cited by 251
Protective Role of the Angiotensin AT 2 Receptor in a Renal Wrap Hypertension Model
Siragy, H. M., & Carey, R. M. (1999) · Hypertension · doi:10.1161/01.hyp.33.5.1237 · Cited by 246
Ferrario, C. M. (2006) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2006.003 · Cited by 240
Jacobsen, P., Andersen, S., Rossing, K., Jensen, B. R., & Parving, H.-H. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00940.x · Cited by 226
Rossing, K., Jacobsen, P., Pietraszek, L., & Parving, H.-H. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2268 · Cited by 225
Jacobsen, P., Andersen, S., Jensen, B. R., & Parving, H.-H. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000054495.96193.bf · Cited by 209
Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
Rossing, K., Christensen, P. K., Jensen, B. R., & Parving, H.-H. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.95 · Cited by 205
Role of Remission Clinics in the Longitudinal Treatment of CKD
Ruggenenti, P., Perticucci, E., Cravedi, P., Gambara, V., Costantini, M., Sharma, S. K., Perna, A., & Remuzzi, G. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007090970 · Cited by 204
Self-citationCampbell, R., Sangalli, F., Perticucci, E., Aros, C., Viscarra, C., Perna, A., Remuzzi, A., Bertocchi, F., Fagiani, L., Remuzzi, G., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00832.x · Cited by 188
Self-citationvan den Meiracker, A. H., Baggen, R. G., Pauli, S., Lindemans, A., Vulto, A. G., Poldermans, D., & Boomsma, F. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249708.44016.5c · Cited by 187
Supramaximal Dose of Candesartan in Proteinuric Renal Disease
Burgess, E., Muirhead, N., de Cotret, P. R., Chiu, A., Pichette, V., & Tobe, S. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008040416 · Cited by 182
Salt Intake and Renal Outcome in Patients with Progressive Renal Disease
Cianciaruso, B., Bellizzi, V., Minutolo, R., A, T., Capuano, A., Conte, G., & Nicola, L. D. (1998) · Mineral and Electrolyte Metabolism · doi:10.1159/000057385 · Cited by 155
Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade
Khosla, N., Kalaitzidis, R., & Bakris, G. L. (2009) · American Journal of Nephrology · doi:10.1159/000237742 · Cited by 155
Persson, F., Rossing, P. R., Reinhard, H., Juhl, T. R., Stehouwer, C. D. A., Schalkwijk, C. G., Danser, A. H. J., Boomsma, F., Frandsen, E. L., & Parving, H. (2009) · Diabetes Care · doi:10.2337/dc09-0168 · Cited by 151
The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications
COOPER, M. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.08.004 · Cited by 147
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus
Hollenberg, N. K., Parving, H., Viberti, G. C., Remuzzi, G., Ritter, S., Zelenkofske, S. L., Kandra, A., Daley, W. L., & Rocha, R. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e328277596e · Cited by 144
Self-citationIs There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension?
Sharma, A. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000132568.71409.a2 · Cited by 136
Aspartic Proteases in Drug Discovery
Eder, J., Hommel, U., Cumin, F., Martoglio, B., & Gerhartz, B. (2006) · Current Pharmaceutical Design · doi:10.2174/138161207779313560 · Cited by 134
ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease
Hilgers, K. F., & Mann, J. F. E. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1341100 · Cited by 126
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy
Jacobsen, P. K. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.6.1019 · Cited by 125
Obesity and Hypertension: Mechanisms, Cardio-Renal Consequences, and Therapeutic Approaches
Reisin, E., & Jack, A. V. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2009.02.010 · Cited by 125
Ruggenenti, P. L., Bettinaglio, P., Pinares, F., & Remuzzi, G. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04140907 · Cited by 109
Self-citationHaller, H. G., Viberti, G. C., Mimran, A., Remuzzi, G., Rabelink, T. J., Ritz, E., Rump, L. C., Ruilope, L. M., Katayama, S., Ito, S., et al. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000202820.56201.e6 · Cited by 106
Self-citationSilvestre, J., Tamarat, R., Senbonmatsu, T., Icchiki, T., Ebrahimian, T. G., Iglarz, M., Besnard, S., Duriez, M., Inagami, T., & Levy, B. I. (2002) · Circulation Research · doi:10.1161/01.res.0000019892.41157.24 · Cited by 105
Nguyen, G., & Danser, A. H. J. (2008) · Experimental Physiology · doi:10.1113/expphysiol.2007.040030 · Cited by 99
Long-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes
Andersen, N. H., Poulsen, P. L., Knudsen, S. T., Poulsen, S. H., Eiskjær, H., Hansen, K. W., Helleberg, K., & Mogensen, C. E. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.273 · Cited by 99
Baba, S. (2001) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00288-1 · Cited by 98
Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection
Perico, N., Benigni, A., & Remuzzi, G. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2685 · Cited by 97
Self-citationAllen, T. J., Waldron, M. J., CASLEY, D. J., Jerums, G., & Cooper, M. E. (1997) · Diabetes · doi:10.2337/diab.46.1.119 · Cited by 79
Ruggenenti, P. L., Perna, A., Ganeva, M. G., Ene‐Iordache, B., & Remuzzi, G. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006060560 · Cited by 70
Self-citationPerico, N., Amuchastegui, S., Colosio, V., Sonzogni, G., Bertani, T., & Remuzzi, G. (1994) · Journal of the American Society of Nephrology · doi:10.1681/asn.v541139 · Cited by 70
Self-citationAnalysis of Factors Causing Hyperkalemia
Takaichi, K., Takemoto, F., Ubara, Y., & Mori, Y. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6415 · Cited by 69
DE'OLIVEIRA, J. M. F., Price, D. A., Fisher, N. D. L., Allan, D. R., McKnight, J. A., Williams, G. H., & Hollenberg, N. K. (1997) · Kidney International · doi:10.1038/ki.1997.394 · Cited by 68
Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes
Eurich, D. T., Majumdar, S. R., Tsuyuki, R. T., & Johnson, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1330 · Cited by 64
Ekinci, E. I., Thomas, G., Thomas, D. M., Johnson, C., MacIsaac, R. J., Houlihan, C. A., Finch, S. J., Panagiotopoulos, S., O’Callaghan, C. J., & Jerums, G. (2009) · Diabetes Care · doi:10.2337/dc08-2297 · Cited by 63
Allen, T. J., Waldron, M. J., CASLEY, D. J., Jerums, G., & Cooper, M. E. (1997) · Diabetes · doi:10.2337/diabetes.46.1.19 · Cited by 63
Tütüncü, N. B., Gürlek, A., & Gedik, O. (2001) · Acta Diabetologica · doi:10.1007/s592-001-8073-2 · Cited by 53
Ruggenenti, P. L., Mosconi, L., Sangalli, F., Casiraghi, F., Gambara, V., Remuzzi, G., & Remuzzi, A. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.055003984.x · Cited by 53
Self-citationLocatelli, F., CARBARNS, I. R. I., Maschio, G., Mann, J. F. E., Ponticelli, C. E., Ritz, E., Alberti, D., Motolese, M., Janin, G., & Zucchelli, P. (1997) · PubMed · Cited by 50
Parving, H., & Hovind, P. H. (2002) · Current Hypertension Reports · doi:10.1007/s11906-002-0069-3 · Cited by 49
Is the ONTARGET renal substudy actually off target?
Ruggenenti, P. L., & Remuzzi, G. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.109 · Cited by 45
Self-citationJerums, G., Allen, T. J., Tsalamandris, C., & Cooper, M. E. (1992) · Kidney International · doi:10.1038/ki.1992.138 · Cited by 39
Zhang, Z., Shahinfar, S., Keane, W. F., Ramjit, D. R., Dickson, T. Z., Gleim, G. W., Mogensen, C. E., de Zeeuw, D., Brenner, B. M., & Snapinn, S. M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080632 · Cited by 39
Overview of randomised trials of ACE inhibitors
Remuzzi, G., & Ruggenenti, P. L. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69172-1 · Cited by 38
Self-citationRenin, Angiotensin, Sodium and Organ Damage
Morgan, T. O. (2003) · Hypertension Research · doi:10.1291/hypres.26.349 · Cited by 34
Du, J. C., Fan, Y., Hitomi, H., et al. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00197.2009 · Cited by 33
Aldosterone breakthrough during ras blockade: A role for endothelins and their antagonists?
Rossi, G. P. (2006) · Current Hypertension Reports · doi:10.1007/s11906-006-0060-5 · Cited by 24
Treatment of isolated systolic hypertension in diabetes mellitus type 2
Os, I., Gudmundsdottir, H., Kjeldsen, S. E., & Oparil, S. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00523.x · Cited by 21
Renin-Angiotensin-Aldosterone System Blockade in Diabetes: Role of Direct Renin Inhibitors
Estacio, R. O. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.2000 · Cited by 15
Weir, M. (1998) · Mineral and Electrolyte Metabolism · doi:10.1159/000057405 · Cited by 15
Aldosterone in clinical nephrology--old hormone, new questions
Becker, G. J., Hewitson, T. D., & Chrysostomou, A. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp256 · Cited by 13
Blood pressure may be sodium-dependent in diabetic patients without overt nephropathy
O’Hare, J. A., Ferriss, J. B., Twomey, B. M., Cole, M., Brady, D., & O’Sullivan, D. J. (1985) · Irish Journal of Medical Science (1971 -) · doi:10.1007/bf02937197 · Cited by 7
Risk : benefit assessment of old medicines
Garattini, S. K., & Bertelè, V. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02197.x · Cited by 4
Cited by
Fibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Kato, M., & Natarajan, R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0135-6 · Cited by 600
Innate immunity in diabetic kidney disease
Tang, S. C. W., & Yiu, W. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0234-4 · Cited by 596
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589
Epigenetic mechanisms in diabetic complications and metabolic memory
Reddy, M. A., Zhang, E., & Natarajan, R. (2015) · Diabetologia · doi:10.1007/s00125-014-3462-y · Cited by 496
Metadata
- Authors
- Ruggenenti, P., Cravedi, P., & Remuzzi, G.
- Venue
- Nature Reviews Nephrology
- Published
- 2010-05-04
- Volume
- 6
- Issue
- 6
- Pages
- 319-330
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- OpenAlex
- W2010320457
- Cited by
- 319
- References
- 114
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.